The real question is to what extent branded companies such as Amgen which are also developing biosimilars want to limit the future role of these products or simply raise the barriers to entry.
Most of the 20-year-old satellite should simply have burnt up on re-entry into the Earth's atmosphere, but modelling work indicated perhaps 500kg could have survived to the surface.
To put it simply, they decide to stay informal because the total costs of entry, operation and exit associated with joining the formal sector are greater than the potential benefits.